ACE-031 is a fusion protein of the activin receptor type IIB (ActRIIB) extracellular domain fused to human IgG1 Fc — a soluble "decoy receptor" designed to sequester myostatin and related TGF-β superfamily ligands that limit muscle growth. Developed by Acceleron Pharma, ACE-031 acts as a molecular sponge for the most potent endogenous muscle growth inhibitors, including myostatin (GDF-8), activin A, GDF-11, and BMP-9 — preventing these ligands from binding their natural receptors and signaling muscle protein synthesis suppression.

Myostatin is the defining endogenous limiter of skeletal muscle mass. Genetic myostatin deficiency — documented in several human children, cattle breeds, and animal models — produces dramatic muscle hypertrophy without apparent adverse effects, demonstrating that physiological muscle mass is constrained well below its biological ceiling by myostatin signaling. Myostatin inhibition has been the most sought-after pharmaceutical target in muscle-wasting disease research for two decades. ACE-031 extends this inhibition to include not just myostatin but the entire family of myostatin-related ligands that converge on ActRIIB — providing broader muscle anabolic signaling enhancement than myostatin-selective antibodies.

In human Phase 2 clinical trials in healthy postmenopausal women, a single dose of ACE-031 produced statistically significant increases in lean body mass (thigh muscle volume by MRI) and bone mineral density within 28 days. This rapid, pronounced effect from a single dose — greater lean mass gain in weeks than typical exercise interventions produce in months — established ACE-031 as one of the most potent anabolic biological agents ever evaluated in controlled human trials. Phase 2 trials in Duchenne Muscular Dystrophy, facioscapulohumeral muscular dystrophy, and other muscle-wasting conditions were also initiated, showing clinically meaningful muscle mass improvements.

The mechanism produces effects beyond muscle: ACE-031 also increases bone density, reduces fat mass, and improves muscle fiber-type distribution toward oxidative (Type I) fibers. The bone effects are attributed to BMP-9 sequestration (which normally suppresses osteoblast activity), while the fat effects reflect ActRIIB's role in adipocyte biology alongside muscle. This makes ACE-031 a multi-tissue anabolic agent with effects on body composition comprehensively, not just muscle isolation.

The program was placed on clinical hold in 2013 after participants developed telangiectasias (dilated capillaries) and some reported epistaxis and gingival bleeding — adverse effects attributed to BMP-9 sequestration affecting vascular development pathways. ACE-031 was not approved and is not a pharmaceutical product; it is available as a research compound. The bleeding effects at Phase 2 human doses were dose-dependent, and research protocols use substantially lower doses with correspondingly different risk profiles.

Dose: 1mg (the available vial size), administered subcutaneously. Frequency and cycling require individual research protocol determination. Combination with Follistatin (if available) covers overlapping and complementary ActRIIB pathway inhibition with different molecular specificity.